Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
4
80%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 2Efficacy & side effects
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (80.0%)
Phase 21 (20.0%)

Trials by Status

completed360%
terminated240%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_2

A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer

NCT01036113
terminatedphase_1

Study of EZN-2208 Pediatric Patients With Solid Tumors

NCT01295697
completedphase_1

EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors

NCT01251926
completedphase_1

A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)

NCT00520390
completedphase_1

A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)

NCT00520637

Clinical Trials (5)

Showing 5 of 5 trials
NCT01036113Phase 2

A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer

Terminated
NCT01295697Phase 1

Study of EZN-2208 Pediatric Patients With Solid Tumors

Terminated
NCT01251926Phase 1

EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors

Completed
NCT00520390Phase 1

A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)

Completed
NCT00520637Phase 1

A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5